A 58-year-old man from Delhi presents with progressive dyspnea on exertion for 3 months, orthopnea, and nocturnal cough. He has a 10-year history of hypertension (currently on amlodipine 5 mg daily) and type 2 diabetes. On examination: BP 160/100 mmHg, HR 92/min, RR 24/min, JVP elevated at 8 cm, bilateral basal crackles, S3 gallop present. Chest X-ray shows pulmonary edema with Kerley B lines. Echocardiography reveals LVEF 35%, dilated left ventricle (LVEDD 62 mm), and severe mitral regurgitation. BNP is 850 pg/mL. What is the most appropriate next step in management?

Explanation

## Clinical Diagnosis This patient has **systolic heart failure (HFrEF)** with LVEF 35%, secondary to longstanding hypertension and diabetes, complicated by functional mitral regurgitation and acute decompensation. **Key Point:** The LVEF ≤40% with clinical signs of heart failure (orthopnea, elevated JVP, crackles, S3 gallop) defines HFrEF and mandates guideline-directed medical therapy (GDMT). ## Management Algorithm for HFrEF ```mermaid flowchart TD A[HFrEF diagnosed<br/>LVEF ≤40%]:::outcome --> B[Initiate GDMT<br/>ACE-I/ARB + BB]:::action B --> C{Tolerated?}:::decision C -->|Yes| D[Add MRA if<br/>K+ normal, eGFR >30]:::action C -->|No| E[Uptitrate gradually<br/>or switch agents]:::action D --> F{LVEF still<br/>≤35% + NYHA II-IV?}:::decision F -->|Yes| G[Evaluate for<br/>ICD/CRT]:::action F -->|No| H[Continue GDMT<br/>+ diuretics PRN]:::action G --> I[Device therapy<br/>if EF remains low]:::action ``` ## Rationale for Correct Answer **High-Yield:** The patient meets criteria for **triple therapy**: 1. **ACE inhibitor** (or ARB) — reduces afterload, prevents remodeling, improves survival [cite:Harrison 21e Ch 297] 2. **Beta-blocker** (carvedilol, metoprolol succinate, or bisoprolol) — reduces mortality in systolic HF 3. **Aldosterone antagonist** (spironolactone/eplerenone) — indicated if LVEF ≤40% and K^+^ normal (here normal renal function presumed) **Clinical Pearl:** This patient also requires **device therapy evaluation** because: - LVEF 35% (≤35%) - NYHA functional class III–IV symptoms (orthopnea, DOE) - Meets criteria for **ICD** (primary prevention) or **CRT** (if QRS >120 ms, which is not stated but should be assessed) Mitral regurgitation is **functional** (secondary to LV dilation), not organic — it will improve with LV remodeling on GDMT and does NOT require acute surgery. ## Why Not the Other Options? | Option | Why Wrong | |--------|----------| | Diuretic monotherapy | Diuretics relieve congestion but do NOT slow disease progression or improve survival; GDMT is mandatory first-line | | ACE-I alone | Incomplete therapy; beta-blocker is essential for mortality reduction in HFrEF; MRA improves outcomes further | | Urgent mitral valve replacement | Functional MR improves with GDMT and LV remodeling; surgery is reserved for severe organic (primary) MR or failed medical management | **Mnemonic:** **ARNI-BB-MRA** = modern HFrEF triple therapy (ARNi or ACE-I/ARB + Beta-Blocker + Mineralocorticoid Receptor Antagonist). SGLT2 inhibitors are now also recommended but not an option here.